BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its financial results for the second quarter ended June 30, 2023; the report also included a business update. Highlights of the report include R&D expenses for the quarter totaled $1.45 million compared with $1.97 million for the same period in 2022; marketing, general and administrative expenses for the quarter reached $1.14 million compared with $1.29 million for the 2022 period; total operating expenses for the quarter amounted to $2.56 million compared with $3.26 million for Q2 2022. The report also showed that financial (loss) income for Q2 totaled $1.16 million loss compared with $0.28 million income for the three months ended June 30, 2022, with net loss for the same period reaching $3.76 million compared with $2.98 million for same period in 2022. Business updates include the creation of a contract development and manufacturing organization (“CDMO”) in parallel to its innovative R&D business unit; the move is designed to leverage its aseptic manufacturing site and laboratories. In addition, the company signed an exclusive license agreement with Max Planck Innovation for development and commercialization of a novel anti-IL-17 NanoAb (VHH antibody) for treatment of autoimmune and inflammatory diseases including psoriasis, and the company is also pursuing a strategic partnership for its COVID-19, self-administered inhaled NanoAb therapeutic/prophylactic. The company also noted that NanoAbs for treatment of additional autoimmune diseases are being developed as part of a research collaboration with Max Planck and University Medical Center Göttingen.
To view the full press release, visit https://ibn.fm/bG5y8
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork